Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,501–1,510 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1501
- Medicine slug
- thiotepa
- Compared field
- volumeOfDistribution
- Comparison state
- not_comparable
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- DENOMINATOR_MISMATCH
- Documents examined
- 12
- Source count
- 8
- Agreement rate
- 0.5
- Recorded readings
1.0 L/kg
- Numeric value
- 1
- Unit
- L/kg
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8c8bb14-0423-e4a3-8bf0-8a66ce05b1bb (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adults administered intravenous thiotepa between 20 mg to 250 mg/m 2 as an intravenous bolus or infusion up to 4 hours, the mean volume of distribution of thiotepa ranged from 1.0 L/kg (30%) to 1.9 L/kg (17%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:493410f3-0733-4f76-8050-6529d96f2a5b (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adults administered intravenous thiotepa between 20 mg to 250 mg/m 2 as an intravenous bolus or infusion up to 4 hours, the mean volume of distribution of thiotepa ranged from 1.0 L/kg (30%) to 1.9 L/kg (17%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b4725eb-95f1-45cc-852f-152beb5f1e2c (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adults administered intravenous thiotepa between 20 mg to 250 mg/m 2 as an intravenous bolus or infusion up to 4 hours, the mean volume of distribution of thiotepa ranged from 1.0 L/kg (30%) to 1.9 L/kg (17%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:add44e98-a042-4e38-b870-beb36693805b (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adults administered intravenous thiotepa between 20 mg to 250 mg/m 2 as an intravenous bolus or infusion up to 4 hours, the mean volume of distribution of thiotepa ranged from 1.0 L/kg (30%) to 1.9 L/kg (17%).
30 L
- Numeric value
- 30
- Unit
- L
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:559e353c-2dc0-16ba-e054-00144ff8d46c (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
The mean volume of distribution (% coefficient of variation) of thiotepa was 30 L/m 2 (44%) or 1.2 L/kg (47%) following a single intravenous infusion of TEPADINA at a dose of 5 mg/kg over 3 hours in pediatric population.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b702dcc9-dd0e-4386-b1e2-f20562fd2ad9 (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
The mean volume of distribution (% coefficient of variation) of thiotepa was 30 L/m2 (44%) or 1.2 L/kg (47%) following a single intravenous infusion of thiotepa at a dose of 5 mg/kg over 3 hours in pediatric population.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cd6ae89-c553-4328-9262-4363610a1f19 (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
The mean volume of distribution (% coefficient of variation) of thiotepa was 30 L/m 2 (44%) or 1.2 L/kg (47%) following a single intravenous infusion of thiotepa at a dose of 5 mg/kg over 3 hours in pediatric population.
1 L/kg
- Numeric value
- 1
- Unit
- L/kg
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ae8063c-ba28-4da2-a94c-8e1a5f75e4b3 (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adults administered intravenous thiotepa between 20 mg to 250 mg/m 2 as an intravenous bolus or infusion up to 4 hours, the mean volume of distribution of thiotepa ranged from 1 L/kg (30%) to 1.9 L/kg (17%).
Projected row 1502
- Medicine slug
- tiagabine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
90%
- Numeric value
- 90
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eeb2d81-c5d7-46a0-aa5c-149b55df71bd (opens source in a new tab)
Tiagabine label
Version not recorded · Effective date not recorded
Tiagabine is nearly completely absorbed (>95%), with an absolute oral bioavailability of about 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c034fe0-cdac-49e1-8e39-592846ea3bec (opens source in a new tab)
Tiagabine label
Version not recorded · Effective date not recorded
Tiagabine is nearly completely absorbed (>95%), with an absolute oral bioavailability of about 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:953ef3cc-e3cb-480f-b9ea-256520fd62b8 (opens source in a new tab)
Tiagabine label
Version not recorded · Effective date not recorded
Tiagabine is nearly completely absorbed (>95%), with an absolute oral bioavailability of about 90%.
Projected row 1503
- Medicine slug
- tiagabine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
7 to 9 hours
- Numeric value
- 7
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eeb2d81-c5d7-46a0-aa5c-149b55df71bd (opens source in a new tab)
Tiagabine label
Version not recorded · Effective date not recorded
The elimination half-life of tiagabine is 7 to 9 hours in normal volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c034fe0-cdac-49e1-8e39-592846ea3bec (opens source in a new tab)
Tiagabine label
Version not recorded · Effective date not recorded
The elimination half-life of tiagabine is 7 to 9 hours in normal volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:953ef3cc-e3cb-480f-b9ea-256520fd62b8 (opens source in a new tab)
Tiagabine label
Version not recorded · Effective date not recorded
The elimination half-life of tiagabine is 7 to 9 hours in normal volunteers.
Projected row 1504
- Medicine slug
- ticagrelor
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 36
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
36%
- Numeric value
- 36
- Unit
- %
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc333c4a-ad63-4d67-a3f7-431ac469d116 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a50eb0b4-1bee-4781-8eba-75e324540d36 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:789606e3-9efa-440c-84f1-f1c56fcbf0cd (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557351f1-47b7-216d-e063-6394a90afb51 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:555d4e44-9bb2-474e-9bea-c549e3261dbb (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4239fc4c-dae6-eb51-e063-6394a90a00d5 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32769721-c1dd-4bd3-90aa-a6cab59d3cd6 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ecb82df-fad2-1f6c-e063-6294a90a9d19 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:425024ab-e092-7a6d-e063-6294a90ae4f3 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5955a5f5-fbc7-8f67-e063-6394a90ada36 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1547e2b6-8858-178e-e063-6394a90abb23 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40ac26dc-2570-de7e-e063-6294a90ade72 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1225fd45-9b56-1671-ee77-cd0c9f2174a5 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c1ca82-99bd-451a-ad77-7fe28c4ae3e8 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7b3f443-e83d-4bf2-0e96-023448fed9a8 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40bb0fb0-2275-4df7-e063-6394a90ade2e (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:751410c1-452b-400b-a640-d31623a6fda3 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c59ea45-6113-6e9e-70b5-3b8c8b3d89b6 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbdc202-bbe4-4aec-b4e9-1f1feb41d819 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c950bd-7f5f-a811-e063-6394a90a0080 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b2d081-c17a-c126-e063-6394a90a5729 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5be5ef20-fc9f-4c3b-a482-83ffd8a3ab47 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3225098b-3138-4aec-a866-de94c3006e8e (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f66384-e2c7-41c5-961f-384918ef58ec (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d68b79ab-3104-410e-a63f-9919a23625af (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7efe86fa-5d19-413a-8b15-e51279b62f3f (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb8fb960-1f0e-40b1-9889-b02296bb3c37 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89c29c9-d2c0-4605-b74f-059e0b104977 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:436d1bef-da01-7d0a-e063-6294a90abd90 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f9bd52a-99a7-4606-92b4-456a917aabef (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32ebf046-73e4-b11b-e063-6294a90a5bf4 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41c5d35c-91de-a8a4-e063-6394a90ac5ff (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:461d810e-5b77-5e53-e063-6294a90a64b0 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30%-42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1c29d47-960f-4fc4-b6ff-399e2c6eec4c (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f73a4db-2c7f-4e42-a914-87aedc2780fb (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37f1d3d7-030f-180a-e063-6294a90a89da (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of ticagrelor is about 36% (range 30% to 42%).
Projected row 1505
- Medicine slug
- ticagrelor
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 36
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc333c4a-ad63-4d67-a3f7-431ac469d116 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (> 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a50eb0b4-1bee-4781-8eba-75e324540d36 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:789606e3-9efa-440c-84f1-f1c56fcbf0cd (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557351f1-47b7-216d-e063-6394a90afb51 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:555d4e44-9bb2-474e-9bea-c549e3261dbb (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4239fc4c-dae6-eb51-e063-6394a90a00d5 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32769721-c1dd-4bd3-90aa-a6cab59d3cd6 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ecb82df-fad2-1f6c-e063-6294a90a9d19 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:425024ab-e092-7a6d-e063-6294a90ae4f3 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5955a5f5-fbc7-8f67-e063-6394a90ada36 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1547e2b6-8858-178e-e063-6394a90abb23 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40ac26dc-2570-de7e-e063-6294a90ade72 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (> 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1225fd45-9b56-1671-ee77-cd0c9f2174a5 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c1ca82-99bd-451a-ad77-7fe28c4ae3e8 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7b3f443-e83d-4bf2-0e96-023448fed9a8 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40bb0fb0-2275-4df7-e063-6394a90ade2e (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:751410c1-452b-400b-a640-d31623a6fda3 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c59ea45-6113-6e9e-70b5-3b8c8b3d89b6 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbdc202-bbe4-4aec-b4e9-1f1feb41d819 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c950bd-7f5f-a811-e063-6394a90a0080 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b2d081-c17a-c126-e063-6394a90a5729 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5be5ef20-fc9f-4c3b-a482-83ffd8a3ab47 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3225098b-3138-4aec-a866-de94c3006e8e (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f66384-e2c7-41c5-961f-384918ef58ec (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d68b79ab-3104-410e-a63f-9919a23625af (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7efe86fa-5d19-413a-8b15-e51279b62f3f (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb8fb960-1f0e-40b1-9889-b02296bb3c37 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89c29c9-d2c0-4605-b74f-059e0b104977 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:436d1bef-da01-7d0a-e063-6294a90abd90 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (> 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f9bd52a-99a7-4606-92b4-456a917aabef (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32ebf046-73e4-b11b-e063-6294a90a5bf4 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41c5d35c-91de-a8a4-e063-6394a90ac5ff (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:461d810e-5b77-5e53-e063-6294a90a64b0 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1c29d47-960f-4fc4-b6ff-399e2c6eec4c (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f73a4db-2c7f-4e42-a914-87aedc2780fb (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37f1d3d7-030f-180a-e063-6294a90a89da (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).
Projected row 1506
- Medicine slug
- ticagrelor
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 36
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
1.5 h
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc333c4a-ad63-4d67-a3f7-431ac469d116 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0-4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a50eb0b4-1bee-4781-8eba-75e324540d36 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:789606e3-9efa-440c-84f1-f1c56fcbf0cd (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median tmax of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557351f1-47b7-216d-e063-6394a90afb51 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:555d4e44-9bb2-474e-9bea-c549e3261dbb (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0 to 4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4239fc4c-dae6-eb51-e063-6394a90a00d5 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32769721-c1dd-4bd3-90aa-a6cab59d3cd6 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ecb82df-fad2-1f6c-e063-6294a90a9d19 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:425024ab-e092-7a6d-e063-6294a90ae4f3 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5955a5f5-fbc7-8f67-e063-6394a90ada36 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1547e2b6-8858-178e-e063-6394a90abb23 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40ac26dc-2570-de7e-e063-6294a90ade72 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0 to 4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1225fd45-9b56-1671-ee77-cd0c9f2174a5 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c1ca82-99bd-451a-ad77-7fe28c4ae3e8 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0-4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7b3f443-e83d-4bf2-0e96-023448fed9a8 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40bb0fb0-2275-4df7-e063-6394a90ade2e (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:751410c1-452b-400b-a640-d31623a6fda3 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c59ea45-6113-6e9e-70b5-3b8c8b3d89b6 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbdc202-bbe4-4aec-b4e9-1f1feb41d819 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0 to 4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c950bd-7f5f-a811-e063-6394a90a0080 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b2d081-c17a-c126-e063-6394a90a5729 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median tmax of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5be5ef20-fc9f-4c3b-a482-83ffd8a3ab47 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3225098b-3138-4aec-a866-de94c3006e8e (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0 to 4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f66384-e2c7-41c5-961f-384918ef58ec (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d68b79ab-3104-410e-a63f-9919a23625af (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7efe86fa-5d19-413a-8b15-e51279b62f3f (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb8fb960-1f0e-40b1-9889-b02296bb3c37 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median tmax of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89c29c9-d2c0-4605-b74f-059e0b104977 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:436d1bef-da01-7d0a-e063-6294a90abd90 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0 to 4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f9bd52a-99a7-4606-92b4-456a917aabef (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32ebf046-73e4-b11b-e063-6294a90a5bf4 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41c5d35c-91de-a8a4-e063-6394a90ac5ff (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:461d810e-5b77-5e53-e063-6294a90a64b0 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0–4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1c29d47-960f-4fc4-b6ff-399e2c6eec4c (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f73a4db-2c7f-4e42-a914-87aedc2780fb (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1.0 to 4.0).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37f1d3d7-030f-180a-e063-6294a90a89da (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Absorption of ticagrelor occurs with a median t max of 1.5 h (range 1 to 4).
Projected row 1507
- Medicine slug
- ticagrelor
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 36
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
88 L
- Numeric value
- 88
- Unit
- L
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc333c4a-ad63-4d67-a3f7-431ac469d116 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a50eb0b4-1bee-4781-8eba-75e324540d36 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:789606e3-9efa-440c-84f1-f1c56fcbf0cd (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557351f1-47b7-216d-e063-6394a90afb51 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:555d4e44-9bb2-474e-9bea-c549e3261dbb (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4239fc4c-dae6-eb51-e063-6394a90a00d5 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32769721-c1dd-4bd3-90aa-a6cab59d3cd6 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ecb82df-fad2-1f6c-e063-6294a90a9d19 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:425024ab-e092-7a6d-e063-6294a90ae4f3 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5955a5f5-fbc7-8f67-e063-6394a90ada36 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1547e2b6-8858-178e-e063-6394a90abb23 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40ac26dc-2570-de7e-e063-6294a90ade72 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady-state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1225fd45-9b56-1671-ee77-cd0c9f2174a5 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c1ca82-99bd-451a-ad77-7fe28c4ae3e8 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7b3f443-e83d-4bf2-0e96-023448fed9a8 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40bb0fb0-2275-4df7-e063-6394a90ade2e (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:751410c1-452b-400b-a640-d31623a6fda3 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c59ea45-6113-6e9e-70b5-3b8c8b3d89b6 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbdc202-bbe4-4aec-b4e9-1f1feb41d819 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c950bd-7f5f-a811-e063-6394a90a0080 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b2d081-c17a-c126-e063-6394a90a5729 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5be5ef20-fc9f-4c3b-a482-83ffd8a3ab47 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3225098b-3138-4aec-a866-de94c3006e8e (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f66384-e2c7-41c5-961f-384918ef58ec (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d68b79ab-3104-410e-a63f-9919a23625af (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7efe86fa-5d19-413a-8b15-e51279b62f3f (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb8fb960-1f0e-40b1-9889-b02296bb3c37 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89c29c9-d2c0-4605-b74f-059e0b104977 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:436d1bef-da01-7d0a-e063-6294a90abd90 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady-state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f9bd52a-99a7-4606-92b4-456a917aabef (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32ebf046-73e4-b11b-e063-6294a90a5bf4 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41c5d35c-91de-a8a4-e063-6394a90ac5ff (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:461d810e-5b77-5e53-e063-6294a90a64b0 (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1c29d47-960f-4fc4-b6ff-399e2c6eec4c (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f73a4db-2c7f-4e42-a914-87aedc2780fb (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37f1d3d7-030f-180a-e063-6294a90a89da (opens source in a new tab)
Ticagrelor label
Version not recorded · Effective date not recorded
Distribution The steady state volume of distribution of ticagrelor is 88 L.
Projected row 1508
- Medicine slug
- tigecycline
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
71%
- Numeric value
- 71
- Unit
- %
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8450bd15-2b06-4fc7-b302-9021312e3f0d (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
) 51.0 (58%) V ss (L) 568 (43%) 639 (48%) a 100 mg initially, followed by 50 mg every 12 hours b 30-minute infusion c 60-minute infusion Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd58e0c3-d8a8-4cf2-96f8-9dd08f309579 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
0.13 (59%) t ½ (h) 27.1 (53%) 42.4 (83%) CL (L/h) 21.8 (40%) 23.8 (33%) CL r (mL/min) 38.0 (82%) 51.0 (58%) V ss (L) 568 (43%) 639 (48%) Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd826e47-1b77-4ffd-bb22-fda3379903b0 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
0.13 (59%) t ½ (h) 27.1 (53%) 42.4 (83%) CL (L/h) 21.8 (40%) 23.8 (33%) CL r (mL/min) 38.0 (82%) 51.0 (58%) V ss (L) 568 (43%) 639 (48%) Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:230484a8-408c-dcc1-d0c4-d9dd9a46831b (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
0.13 (59%) t ½ (h) 27.1 (53%) 42.4 (83%) CL (L/h) 21.8 (40%) 23.8 (33%) CL r (mL/min) 38.0 (82%) 51.0 (58%) V ss (L) 568 (43%) 639 (48%) Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e9a34af-8dee-4ba2-9157-2f5cb46958a9 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
0.13 (59%) t ½ (h) 27.1 (53%) 42.4 (83%) CL (L/h) 21.8 (40%) 23.8 (33%) CL r (mL/min) 38.0 (82%) 51.0 (58%) V ss (L) 568 (43%) 639 (48%) Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50605463-2dc2-4b27-bc51-4d87bb9a8539 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
– 0.13 (59%) t 1/2 (h) 27.1 (53%) 42.4 (83%) CL (L/h) 21.8 (40%) 23.8 (33%) CL r (mL/min) 38 (82%) 51 (58%) V ss (L) 568 (43%) 639 (48%) Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cbefeb0-7d63-4c49-9906-384acc53dd15 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
0.13 (59%) t ½ (h) 27.1 (53%) 42.4 (83%) CL (L/h) 21.8 (40%) 23.8 (33%) CL r (mL/min) 38.0 (82%) 51.0 (58%) V ss (L) 568 (43%) 639 (48%) Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ccdb48e-c14a-4eeb-348c-4920ccfd7465 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
0.13 (59%) t ½ (h) 27.1 (53%) 42.4 (83%) CL (L/h) 21.8 (40%) 23.8 (33%) CL r (mL/min) 38.0 (82%) 51.0 (58%) V ss (L) 568 (43%) 639 (48%) Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 mcg/mL).
Projected row 1509
- Medicine slug
- tigecycline
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
500 to 700 L
- Numeric value
- 500
- Unit
- L
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8450bd15-2b06-4fc7-b302-9021312e3f0d (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd58e0c3-d8a8-4cf2-96f8-9dd08f309579 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd826e47-1b77-4ffd-bb22-fda3379903b0 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:230484a8-408c-dcc1-d0c4-d9dd9a46831b (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e9a34af-8dee-4ba2-9157-2f5cb46958a9 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50605463-2dc2-4b27-bc51-4d87bb9a8539 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cbefeb0-7d63-4c49-9906-384acc53dd15 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ccdb48e-c14a-4eeb-348c-4920ccfd7465 (opens source in a new tab)
Tigecycline label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues.
Projected row 1510
- Medicine slug
- timolol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 34
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bc40b2c-65eb-4095-87e6-4752d5b19a3a (opens source in a new tab)
Timolol label
Version not recorded · Effective date not recorded
The drug half-life in plasma is approximately 4 hours and this is essentially unchanged in patients with moderate renal insufficiency.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ae775f4-340c-4bf4-aa49-8a31daba0f8b (opens source in a new tab)
Timolol label
Version not recorded · Effective date not recorded
The half-life of timolol in plasma is approximately 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57c62928-63d8-4505-9b9e-c085a3a12c95 (opens source in a new tab)
Timolol label
Version not recorded · Effective date not recorded
The drug half-life in plasma is approximately 4 hours and this is essentially unchanged in patients with moderate renal insufficiency.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cebc9a5e-0bdb-4f23-9b2c-cde543b62fb6 (opens source in a new tab)
Timolol label
Version not recorded · Effective date not recorded
The half-life of timolol in plasma is approximately 4 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1500Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.